肝切除术后抗凝血酶III给药的多中心随机对照试验(HiSCO-05)
日本广岛7家医院纳入肝切除术后合并凝血功能障碍的141例患者,随机分为抗凝血酶III给药组(n=64)与未给药组(n=77),主要终点为肝切除术后肝衰竭发生率。两组发生率相近(28.1% vs 28.5%,P=.953),给药未显著预防肝切除术后肝衰竭,术后凝血功能障碍治疗本身安全无不良事件。
要点
- 肝切除术后抗凝血酶III给药未降低肝切除术后肝衰竭发生率(28.1% vs 28.5%,P=.953)。
- 给药组并发症发生率17.2%,未给药组11.7%(P=.351)。
- BMI≥25、总胆红素≥1.5 mg/dL、术后DIC评分≥5为肝切除术后肝衰竭独立危险因素。
核心结论
- 肝切除术后给予抗凝血酶III在预防肝切除术后肝衰竭方面未见显著差异,可能通过抑制凝血功能障碍发挥作用。
主要发现
- 肝切除术后肝衰竭发生率未给药组28.5%、给药组28.1%(P=.953)。
- 并发症发生率给药组17.2%、未给药组11.7%(P=.351)。
- 全研究组多因素分析显示BMI≥25、总胆红素≥1.5 mg/dL、术后DIC评分≥5为肝切除术后肝衰竭独立危险因素。
- 术后凝血功能障碍治疗实施安全,无不良事件。
临床怎么用
- 肝切除术后合并凝血功能障碍患者不应期望通过抗凝血酶III给药来降低肝切除术后肝衰竭风险。
- 对BMI≥25、总胆红素≥1.5 mg/dL或术后DIC评分≥5的患者应加强肝切除术后肝衰竭风险监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Posthepatectomy liver failure is a poor prognostic factor after hepatectomy. Various preventive treatments have been tried; however, there are no clinical trials that use posthepatectomy liver failure as the primary endpoint, and the clinical effects of posthepatectomy liver failure have not been fully verified. The aim of this study was to investigate whether administration of antithrombin III can prevent posthepatectomy liver failure in patients with coagulopathy after hepatectomy. This study also evaluated the safety of AT-III administration after hepatectomy. METHODS: The current study enrolled 141 patients diagnosed with coagulopathy after hepatectomy between October 2015 and September 2018 at 7 hospitals in Hiroshima, Japan (HiSCO group). Patients were randomized to undergo either administration of antithrombin III (n = 64) or non-administration (n = 77). The primary endpoint was the incidence of posthepatectomy liver failure. This randomized controlled trial was registered with the University Medical Information Network Clinical Trial Registry (UMIN000018852). RESULTS: Treatment for postoperative coagulopathy was performed safely without adverse events. The incidence of posthepatectomy liver failure was similar in both treatment groups (nonadministration of antithrombin III group, 28.5%, versus administration of antithrombin III group, 28.1%; P = .953) The rate of morbidity was higher in the administration group than the non-administrated group (17.2% vs 11.7%, P = .351). Following the multivariate analysis of the whole study group, body mass index ≥25, total bilirubin ≥1.5 mg/dL, and the disseminated intravascular coagulation score ≥5 postoperatively were the independent risk factors for posthepatectomy liver failure. CONCLUSION: This study showed that the administration of antithrombin III resulted in no significant difference in preventing posthepatectomy liver failure, possibly through suppressing coagulopathy.
引用
- Kuroda S, Kobayashi T, Tashiro H, et al. A multicenter randomized controlled trial comparing administration of antithrombin III after liver resection (HiSCO-05 trial). Surgery. 2021. PMID: 33926704. doi:10.1016/j.surg.2021.03.057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。